Perfusion MR imaging of brain tumors

Topics in Magnetic Resonance Imaging

Volumn 15, Issue 5, 2004, Pages 278-289

  Cha, Soonmee ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Box 0628 ^*  (United States)

Author keywords

Brain tumor; Glioma; Perfusion MR imaging

Indexed keywords

CONTRAST MEDIUM;

BRAIN INJURY; BRAIN LYMPHOMA; BRAIN METASTASIS; BRAIN TUMOR; CANCER GRADING; CANCER MORTALITY; CANCER THERAPY; DEMYELINATING DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFUSION WEIGHTED IMAGING; DISABILITY; GLIOMA; HEMODYNAMICS; HUMAN; IMAGE PROCESSING; MENINGIOMA; METABOLISM; MORBIDITY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PERFUSION WEIGHTED IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TUMOR DIAGNOSIS; TUMOR RECURRENCE; CANCER STAGING; DIFFERENTIAL DIAGNOSIS; METASTASIS; METHODOLOGY; PATHOLOGY;

BRAIN NEOPLASMS; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING;

EID: 21644453422     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002142-200410000-00002     Document Type: Review

References (63)

1. Davis FG, McCarthy BJ, Berger MS. Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base. Neuro-oncology. 1999;1:205-211.
2. Surawicz TS, McCarthy BJ, Kupelian V, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro-oncology. 1999;1:14-25.
3. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-29.
4. Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology. 1985;35:219-226.
5. Longstreth WT Jr, Dennis LK, McGuire VM, et al. Epidemiology of intracranial meningioma. Cancer. 1993;72:639-648.
6. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995;45:8-30.
7. Patchell RA. Brain metastases. Neurol Clin. 1991;9:817-827.
8. Posner JB. Management of brain metastases. Rev Neurol. 1992;148:477-487.
9. Cha S, Pierce S, Knopp EA, et al. Dynamic contrast-enhanced t2*-weighted mr imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol. 2001;22:1109-1116.
10. Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients [see comments]. Ann Neurol. 1993;33:18-27.
11. De Stefano N, Caramanos Z, Preul MC, et al. in vivo differentiation of astrocytic brain rumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging. Ann Neurol. 1998;44:273-278.
12. Hutter A, Schwetye KE, Bierhals AJ, et al. Brain neoplasms: epidemiology, diagnosis, and prospects for cost-effective imaging. Neuroimaging Clin North Am. 2003;13:237-250.
13. Rosen BR, Belliveau JW, Vevea JM, et al. Perfusion imaging with NMR contrast agents. Magn Reson Med. 1990;14:249-265.
14. Weisskoff R, Belliveau J, Kwong K, et al. Functional MR imaging of capillary hemodynamics. In: Potchen E, ed. Magnetic Resonance Angiography: Concepts and Applications. St. Louis, MO: Mosby, 1993:473-484.
15. Zierler KL. Theoretical basis of indicator-dilution methods for measuring flow and volume. Circ Res. 1962;10:393-407.
16. Axel L. Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis. Radiology. 1980;137:679-686.
17. Aronen HJ, Gazit JE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology. 1994;191:41-51.
18. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol. 1998;171:1479-1486.
19. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology. 1999;211:791-798.
20. Sugahara T, Korogi Y, Shigematsu Y, et al. Perfusion-sensitive MRI of cerebral lymphomas: a preliminary report. J Comput Assist Tomogr. 1999;23:232-237.
21. Zierler KL. Circulation times and the theory of indicator-dilution methods for determining blood flow and volume. In: Handbook of Physiology. Baltimore: Williams & Wilkins, 1962:585-615.
22. Kim SG. Quantification of relative cerebral blood flow change by flow-sensitive alternating inversion recovery (FAIR) technique: application to functional mapping. Magn Reson Med. 1995;34:293-301.
23. Edelman RR. Siewert B, Darby DG, et al. Qualitative mapping of cerebral blood flow arid functional localization with echo-planar MR imaging and signal targeting with alternating radio frequency. Radiology. 1994;192:513-520.
24. Zaharchuk G, Ledden PJ, Kwong KK, et al. Multislice perfusion and perfusion territory imaging in humans with separate label and image coils. Magn Reson Med. 1999;41:1093-1098.
25. Young IR, Cox IJ, Coutts GA, et al. Some considerations concerning susceptibility, longitudinal relaxation time constants and motion artifacts in vivo human spectroscopy. NMR Biomed. 1989;2:329-339.
26. Chaudhry IH, O'Donovan DG, Brenchley PE, et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology. 2001;39:409-415.
27. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res. 1995;55:1189-1193.
28. Rutten EH, Doesburg VVH, Slooff JL. Histologic factors in the grading and prognosis of astrocytoma grade I-IV J Neurooncol. 1992;13:223-230.
29. Stratmann A, Machein MR, Plate KH. Anti-angiogenic gene therapy of malignant glioma. Acta Neurochir Suppl. 1997;68:105-110.
30. Sipos EP, Brem H. Local anti-angiogenic brain tumor therapies. J Neurooncol. 2000;50:181-188.
31. Bernsen HJ, van der Kogel AJ. Antiangiogenic therapy in brain tumor models. J Neurooncol. 1999;45:247-255.
32. Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. A JNR Am J Neuroradiol. 2000;21:881-890.
33. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendroglimoas. AJMR Am J Neuroradiol. 2004;25:214-221.
34. Cha S, Tihan T, Crawford F, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol. (in press).
35. Bagley LJ, Grossman RI, Judy KD, et al. Gliomas: correlation of magnetic susceptibility artifact with histologic grade. Radiology. 1997:202:511-516.
36. Vince GH, Wagner S, Pietsch T, et al. Heterogeneous regional expression patterns of matrix metalloproteinases in human malignant gliomas. Int J Dev Neurosci. 1999;17:437-445.
37. Adamek D, Moskala M, Kaluza J, et al. CT-guided stereotactic biopsy of brain: three years of experience. Folia Neuropathol. 1999;37:143-147.
38. Vaquero J, Martinez R, Manrique M. Stereotactic biopsy for brain tumors: is it always necessary? Surg Neurol. 2000;53:432-437; discussion 437-438.
39. Babu R, Huang PP, Epstein F, et al. Late radiation necrosis of the brain: case report. J Neuro-oncology. 1993;17:37-42.
40. Dooms GC, Hecht S, Brant-Zawadzki M, et al. Brain radiation lesions: MR imaging. Radiology. 1986;158:149-155.
41. Morris JG, Grattan-Smith P, Panegyres PK, et al. Delayed cerebral radiation necrosis. Q J Med. 1994;87:119-129.
42. Hopewell JW, Calvo W, Jaenke R, et al. Microvasculature and radiation damage. Recent Results Cancer Res. 1993;130:1-16.
43. Mork SJ, Halvorsen TB, Lindegaard KF, et al. Oligodendroglioma: histologic evaluation and prognosis. J Neuropathol Exp Neurol. 1986;45:65-78.
44. Reiche W, Grunwald I, Hermann K, et al. Oligodendrogliomas. Acta Radiol. 2002;43:474-482.
45. Christov C, Gherardi RK. Vascular endothelial growth factor (VEGF) likely contributes to oligodendroglioma angiogenesis. Acta Neuropathol (Berl). 1999;97:429-432.
46. Long DM. Capillary ultrastructure in human metastatic brain tumors. J Neurosurg. 1979;51:53-58.
47. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncology. 2000;2:45-59.
48. Law M, Cha S, Knopp EA, et al. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology. 2002;222:715-721.
49. Bertossi M, Virgintino D, Maiorano E, et al. Ultrastructural and morphometric investigation of human brain capillaries in normal and peritumoral tissues. Ultrastruct Pathol. 1997;21:41-49.
50. Kelly PJ, Daumas-Duport C, Scheithauer BE, et al. Stereotactic histologic correlations of computed tomography and magnetic resonance imaging defined abnormalities in patients with glial neoplasms. Mayo Clin Proc. 1987;62:450-459.
51. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncology. 1999;43:199-201.
52. Eby NL, Grufferman S, Flannelly CM, et al. Increasing incidence of primary brain lymphoma in the US. Cancer. 1988;62:2461-2465.
53. Jiddane M, Nicoli F, Diaz P, et al. Intracranial malignant lymphoma: report of 30 cases and review of the literature. J Neurosurg. 1986;65:592-599.
54. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-123.
55. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92:261-266.
56. Tallroth K, Katevuo K, Holsti L, et al. Angiography and computed tomography in the diagnosis of primary lymphoma of the brain. Clin Radiol. 1981;32:383-388.
57. Reni M, Ferreri AJ, Garancini MP, et al. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol. 1997;8:227-234.
58. Herrlinger U, Schabet M. Clemens M, et al. Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma. Acta Neurol Scand. 1998;97:257-264.
59. Dagher AP, Smirnaiotopoulos J. Tumefactive demyelinating lesions. Neuroradiology. 1996;38:560-565.
60. Giang DW, Poduri KR, Eskin TA, et al. Multiple sclerosis masquerading as a mass lesion. Neuroradiology. 1992;34:150-154.
61. Kurihara N, Takahashi S, Furuta A, et al. MR imaging of multiple sclerosis simulating brain tumor. Clin Imaging. 1996;20:171-177.
62. Zagzag D, Miller DC, Kleinman GM, et al. Demyelinating disease versus tumor in surgical neuropathology. Clues to a correct pathological diagnosis. Am J Surg Pathol. 1993;17:537-545.
63. Nesbit GM, Forbes GS, Scheithauer BW, et al. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology. 1991;180:467-474.